 
        
        
        Liproxstatin-1 是一种选择性的脂肪氧化酶抑制剂,对脂肪氧化酶具有高亲和力,IC50 值为 22 nM。Liproxstatin-1 具有抗氧化和抗炎作用,可用于脂肪代谢和氧化应激相关疾病的研究。Liproxstatin-1 是一种有效的 ferroptosis 抑制剂。
 
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 产品名称 | Ferroptosis ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ferrostatin-1 | ++ Ferroptosis, EC50: 60 nM | 98% | |||||||||||||||||
| Liproxstatin-1 | +++ ferroptosis, IC50: 22 nM | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 | 
 | 
| 描述 | Liproxstatin-1 acts as a powerful inhibitor of ferroptosis, blocking ferroptotic cell death with an IC50 value of 22 nM[1]. | 
| 体内研究 | Liproxstatin-1 (10 mg/kg, i.p.) inhibits ferroptosis in human cells, Gpx4/kidney, and in a model of ischemia/reperfusion-induced tissue injury[1]. | 
| 体外研究 | Liproxstatin-1 exhibits antiferroptotic effects, with an IC50 value of around 38 nM in mouse embryonic fibroblasts[2]. | 
| 作用机制 | Liproxstatin-1 is a spiroquinoxalinamine derivative that suppresses ferroptosis via lipid peroxide scavenging in vivo. The benzene ring and higher HOMO energy have beneficial effect on increasing the lipid radical scavenging activity. | 
| Concentration | Treated Time | Description | References | |
| MOLP-8 | 1 µM | 10 h | Inhibited ferroptosis in LILRB1-KD MM cells | Nat Commun. 2024 Jul 9;15(1):5767. | 
| ARP-1 | 1 µM | 10 h | Inhibited ferroptosis in LILRB1-KD MM cells | Nat Commun. 2024 Jul 9;15(1):5767. | 
| MDA-LM2 | 1 µM | 1 hour | To evaluate the inhibitory effect of Liproxstatin-1 on TBHP-induced cell death | Nat Cancer. 2023 May;4(5):682-698. | 
| NCI-H522 cells | 0.25 μM | 3 days | Liproxstatin-1, as a selective ferroptosis inhibitor, was used to rescue cell death induced by cytotoxic analogs. All analogs of the amide series showed significant cytotoxicity in NCI-H522 cells, which was completely rescued in the presence of Liproxstatin-1. | J Med Chem. 2022 Sep 8;65(17):11788-11817. | 
| HIEC (human normal small intestinal epithelial cell line) | 1 μM | 24 h | Liproxstatin-1 significantly reversed hypoxia-induced cell death in HIEC, indicating that the mode of cell death induced by hypoxia was predominantly ferroptosis. | flower exosome-like nanoparticles attenuates gastric and small intestinal mucosal ferroptosis caused by hypoxia through inhibiting HIF-1α- and HIF-2α-mediated lipid peroxidation. J Nanobiotechnology. | 
| NGEC (human normal gastric epithelial cell line) | 1 μM | 24 h | Liproxstatin-1 significantly reversed hypoxia-induced cell death in NGEC, indicating that the mode of cell death induced by hypoxia was predominantly ferroptosis. | flower exosome-like nanoparticles attenuates gastric and small intestinal mucosal ferroptosis caused by hypoxia through inhibiting HIF-1α- and HIF-2α-mediated lipid peroxidation. J Nanobiotechnology. | 
| A375P cells | 2 μM | 24 h | To measure lipid peroxidation, results showed that Liproxstatin-1 significantly reversed DC661-induced lipid peroxidation | J Clin Invest. 2023 Apr 17;133(8):e164596. | 
| A375P cells | 2 μM | 24 h | To measure lipid peroxidation, Liproxstatin-1 significantly reversed DC661-induced lipid peroxidation | J Clin Invest. 2023 Apr 17;133(8):e164596. | 
| HK-2 cells | 0.5 µM | 24 h | To investigate the effect of Liproxstatin-1 on oxalate-induced ferroptosis in HK-2 cells, results showed that Liproxstatin-1 inhibited oxalate-induced ferroptosis. | J Transl Med. 2024 Jan 2;22(1):9. | 
| human melanoma cells | 1 μM | 24 h | To test the effect of Liproxstatin-1 on ferroptosis in melanoma cells, the results showed that Liproxstatin-1 blocked the effect of Erastin on cell count reduction. | Nature. 2020 Sep;585(7823):113-118. | 
| Administration | Dosage | Frequency | Description | References | ||
| Mice | MM model | Intraperitoneal injection | 15 mg/kg | Daily | Reversed the inhibition of MM progression induced by LILRB1 deficiency | Nat Commun. 2024 Jul 9;15(1):5767. | 
| Mice | Kidney stone mouse model | Injection | 10 mg/kg | 15 days | To investigate the protective effect of Liproxstatin-1 on CaOx-induced kidney injury, results showed that Liproxstatin-1 alleviated CaOx-induced kidney injury. | J Transl Med. 2024 Jan 2;22(1):9. | 
| Mice | NSG and C57BL mice | Intraperitoneal injection | 20 mg/kg | Daily injections until the end of the experiment | To test the effect of Liproxstatin-1 on the survival of melanoma cells in the blood, the results showed that Liprox pre-treatment significantly increased metastatic disease burden in most efficiently metastasizing melanomas. | Nature. 2020 Sep;585(7823):113-118. | 
| BALB/c nude mice | Footpad implantation nude mouse model | Intraperitoneal injection | 10 mg/kg | Once daily for 20 days | Liproxstatin-1, as a ferroptosis inhibitor, was used to study its effect on tumor growth and metastasis. The results showed that Liproxstatin-1 slightly promoted tumor growth but had no significant effect on lymph node metastasis. | Cell Death Dis. 2023 Jan 20;14(1):48 | 
| Dose | Mice: 5 mg/kg, 10 mg/kg[2] (i.p.); 1 mg/kg[2] (i.v.); | ||||||||||||||||||||||||
| Administration | i.p., i.v. | ||||||||||||||||||||||||
| Pharmacokinetics | 
 | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 2.93mL 0.59mL 0.29mL | 14.67mL 2.93mL 1.47mL | 29.34mL 5.87mL 2.93mL | |
| CAS号 | 950455-15-9 | 
| 分子式 | C19H21ClN4 | 
| 分子量 | 340.85 | 
| SMILES Code | ClC1=CC(CNC(C23CCNCC2)=NC4=C(N3)C=CC=C4)=CC=C1 | 
| MDL No. | MFCD14948691 | 
| 别名 | |
| 运输 | 蓝冰 | 
| InChI Key | YAFQFNOUYXZVPZ-UHFFFAOYSA-N | 
| Pubchem ID | 135735917 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, sealed in dry, store in freezer, under -20°C | 
| 溶解方案 | DMSO: 30 mg/mL(88.02 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 
 
 
 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1